KA/EN
Register
Medicines reference
Search
Search
Active substance

Sulbactam

Favourites

Beta-lactamase inhibitor. No registration in force in Georgia. Forms: powder.

Dose and use

Doses

We have no dose with a cited source for this substance yet.

Before use

Safety information

No sourced safety entry is currently shown. This does not mean the substance is risk-free.

Latin name
Sulbactam
Georgian name
სულბაქტამი
Authorisation status
Human medicine, cascade use
No veterinary authorisation was found in any register checked. Veterinary use is off-label, under the prescribing cascade.
Registered in Georgia
0 of 1 forms
Products
Speybact
Controlled in Georgia
No
Checked against the narcotics law, Annex 1, lists I-IV, and Order No. 22/n.
Verified on: 16 Oct 2026
All forms and registration1

Registration in Georgia and abroad: the register, number, validity and source are behind (i).

Speybact 1.5 g, Powder

powder for solution for injection, human medicine
vetman assessment
vetman’s 10-point assessment brings together a product’s regulatory credibility, clinical efficacy, safety and practicality. Cost-effectiveness is assessed only when reliable data are available. It is informational and does not replace a veterinarian’s clinical judgment for an individual patient.
Dog Hospital IV treatment of a serious susceptible bacterial infection; culture-directed where possible, with empirical use limited to strong suspicion and prompt reassessment/de-escalation
Not rateable
No numerical score assigned
vetman assessment

Speybact

1.5 g, powder for solution for injection, human medicine
Assessed clinical scopeDog · Hospital IV treatment of a serious susceptible bacterial infection; culture-directed where possible, with empirical use limited to strong suspicion and prompt reassessment/de-escalation · Intravenous
Care settingVeterinary hospital use with sampling/culture, source control, aseptic reconstitution, frequent IV administration, renal/hepatic review and clinical/microbiological reassessment
vetman score Not rateable No numerical score assigned
Evidence confidence: Low Georgia: Suspended · № რ-035044 · Verified on 22 Oct 2026 Off-label use
Not rateable

The ampicillin-sulbactam combination has direct canine PK and a veterinary formulary regimen, but this exact Speybact registration is suspended for absent GMP evidence. Current lawful supply and batch quality are unresolved, so the exact presentation cannot receive a responsible clinical score.

The active combination and veterinary IV use are clinically interpretable, but the exact product remains unscoreable while its Georgian registration is suspended for absent GMP evidence and current batch quality is unresolved. Comparator quality cannot validate Speybact.

Important safety and use flags

  • This is a human product. All dog/cat use is off-label and must follow veterinary antimicrobial governance.
  • The Georgian registration is suspended because the register reports no GMP certificate. Retail availability does not mean active authorisation or verified current batch quality.
  • Reserve for a serious proven or strongly suspected susceptible bacterial infection. Obtain samples before treatment when feasible, review culture/MIC and de-escalate to the narrowest effective agent.
  • Antibiotic therapy does not replace drainage, debridement, foreign-body removal, surgery or other source control, and this product is not routine prophylaxis or minor-infection therapy.
  • The 10-30 mg/kg dose is the total 2:1 ampicillin+sulbactam mixture. Do not interpret it as 10-30 mg/kg of ampicillin plus additional sulbactam.
  • Direct critically ill dog PK shows variable target attainment. Do not assume Enterobacterales or resistant-organism coverage without susceptibility and patient-context review.
  • Direct feline combination PK, outcome and exact-product evidence were not located. Cat efficacy and safety confidence are lower and extrapolation must be explicit.
  • Prepare ex tempore, maintain asepsis and compatibility, and verify the current exact pack for post-reconstitution limits. The human IM label does not establish a companion-animal IM regimen.
  • Avoid in serious beta-lactam hypersensitivity/cross-reactivity or prior ampicillin-sulbactam cholestatic injury. Adjust for renal impairment and consider sodium load, seizures at excessive exposure, GI/hepatic injury and cytopenias.
  • Never reconstitute or mix with an aminoglycoside because ampicillin can inactivate it in vitro. Monitor clinical response, culture/MIC, renal/hepatic status, CBC, GI tolerance and bacterial/fungal superinfection.
Assessment sources
  1. Speybact manufacturer instruction2017
  2. Speybact GE register audit2026
  3. Ampicillin-sulbactam comparator label2026
  4. MSD veterinary ampicillin-sulbactam dose2026
  5. AAFP/AAHA stewardship2022
  6. Canine septic-peritonitis PK2022
  7. Critically ill dog PK2025
  8. Dog combination PK1990
Assessed: 22 Oct 2026No axis or overall score is shown when the available evidence does not support a responsible numerical assessment.
Cat Hospital IV treatment of a serious susceptible bacterial infection; culture-directed where possible, with empirical use limited to strong suspicion and prompt reassessment/de-escalation
Not rateable
No numerical score assigned
vetman assessment

Speybact

1.5 g, powder for solution for injection, human medicine
Assessed clinical scopeCat · Hospital IV treatment of a serious susceptible bacterial infection; culture-directed where possible, with empirical use limited to strong suspicion and prompt reassessment/de-escalation · Intravenous
Care settingVeterinary hospital use with sampling/culture, source control, aseptic reconstitution, frequent IV administration, renal/hepatic review and clinical/microbiological reassessment
vetman score Not rateable No numerical score assigned
Evidence confidence: Low Georgia: Suspended · № რ-035044 · Verified on 22 Oct 2026 Off-label use
Not rateable

A veterinary formulary regimen exists, but direct feline combination evidence is sparse and this exact Speybact registration is suspended for absent GMP evidence. Current lawful supply and batch quality are unresolved, so the exact presentation cannot receive a responsible clinical score.

The active combination and veterinary IV use are clinically interpretable, but the exact product remains unscoreable while its Georgian registration is suspended for absent GMP evidence and current batch quality is unresolved. Comparator quality cannot validate Speybact.

Important safety and use flags

  • This is a human product. All dog/cat use is off-label and must follow veterinary antimicrobial governance.
  • The Georgian registration is suspended because the register reports no GMP certificate. Retail availability does not mean active authorisation or verified current batch quality.
  • Reserve for a serious proven or strongly suspected susceptible bacterial infection. Obtain samples before treatment when feasible, review culture/MIC and de-escalate to the narrowest effective agent.
  • Antibiotic therapy does not replace drainage, debridement, foreign-body removal, surgery or other source control, and this product is not routine prophylaxis or minor-infection therapy.
  • The 10-30 mg/kg dose is the total 2:1 ampicillin+sulbactam mixture. Do not interpret it as 10-30 mg/kg of ampicillin plus additional sulbactam.
  • Direct critically ill dog PK shows variable target attainment. Do not assume Enterobacterales or resistant-organism coverage without susceptibility and patient-context review.
  • Direct feline combination PK, outcome and exact-product evidence were not located. Cat efficacy and safety confidence are lower and extrapolation must be explicit.
  • Prepare ex tempore, maintain asepsis and compatibility, and verify the current exact pack for post-reconstitution limits. The human IM label does not establish a companion-animal IM regimen.
  • Avoid in serious beta-lactam hypersensitivity/cross-reactivity or prior ampicillin-sulbactam cholestatic injury. Adjust for renal impairment and consider sodium load, seizures at excessive exposure, GI/hepatic injury and cytopenias.
  • Never reconstitute or mix with an aminoglycoside because ampicillin can inactivate it in vitro. Monitor clinical response, culture/MIC, renal/hepatic status, CBC, GI tolerance and bacterial/fungal superinfection.
Assessment sources
  1. Speybact manufacturer instruction2017
  2. Speybact GE register audit2026
  3. Ampicillin-sulbactam comparator label2026
  4. MSD veterinary ampicillin-sulbactam dose2026
  5. AAFP/AAHA stewardship2022
Assessed: 22 Oct 2026No axis or overall score is shown when the available evidence does not support a responsible numerical assessment.
Composition / strength
Ampicillin1000 mg Sulbactam500 mg
Formulation Type
Powder
Administration route
Intravenous, Intramuscular
Registration
Georgia Suspended
Suspended or cancelled
Human (Ministry of Health, RAMA)
№ რ-035044
Verified on: 22 Oct 2026
 EU Not confirmed
Verified on: 22 Oct 2026
 UK Not confirmed
Verified on: 22 Oct 2026
 US Not confirmed
Verified on: 22 Oct 2026
Controlled in Georgia
No
Checked against the narcotics law, Annex 1, lists I-IV, and Order No. 22/n.
Verified on: 16 Oct 2026
Information not fully verified Exact vial: ampicillin 1 g plus sulbactam 0.5 g. Veterinary guidance gives the combined mixture 10-30 mg/kg IV q6-8h for dogs and cats; do not read it as an ampicillin-only dose. Prepare ex tempore and aseptically according to the public manufacturer instruction; verify the current pack for post-reconstitution limits. Keep aminoglycosides physically separate, sample/culture when feasible and reassess/de-escalate promptly. No companion-animal IM regimen is established.

Professional reference for veterinary professionals. Not advertising and not a substitute for the product label/SPC.

For veterinary professionals only. It does not replace clinical judgement or the product label; check the dose in the official label (SPC). vetman is not liable for harm caused by using this information.

Trademarks belong to their owners; vetman is not affiliated with the manufacturers and receives no payment from them.

The database is protected under Chapter VII of the Law of Georgia on Copyright and Related Rights; automated or bulk copying is prohibited.

This reference is still growing. Missing a product? Let us know. · Report an error or request an addition · Updated: 23 Oct 2026

All of this shows in vetman as you prescribe

The dose for the patient's weight, registration in Georgia and controlled status, right on the prescription.

Register Demo ↗